Reports and Briefs on Pharmaceuticals in Asia-Pacific

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

Type Product title / description Pub Price
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

Pricing and Reimbursement: Innovative Risk-Sharing Strategies - Ensuring market entry through risk-sharing schemes

An overview of risk-sharing agreements and their utilization in the UK, US, Italy and Australia. The pros and cons of risk-sharing agreements are discussed and key strategic recommendations, supported by in depth case study analysis.

Published By Datamonitor
16 Jul 2009 $3800
Buy

Order this report by October 22nd 2010 and receive a 50% discount

To take advantage of this offer enter Promo Code Orphan50 when prompted in the checkout

More information

Report
Report

Orphan Drug Strategies - A route to unlocking new commercial opportunities

Overview of orphan drug strategies in the seven major markets, providing insight into developmental and commercial drivers and resistors, and Pharma's growing focus on targeting niche indications as the primary care blockbuster era nears its end.

Published By Datamonitor
02 Oct 2009 $3800
Buy
Report
Report

Mapping the Healthcare Landscape - Bringing pharmaceuticals into focus

Diversification is one strategy Big Pharma is using to contend with the oncoming patent cliff, however, Datamonitor has analyzed ten sectors within healthcare and concluded that remaining pharma-focused will lead to maximum revenue growth.

Published By Datamonitor
12 Nov 2009 $7600
Buy
Report
Report

2009 Pharmaceutical M&A Overview

An overview of M&A trends for the top 150 global pharmaceutical companies during 2008 and 2009 with discussion of the drivers of recent deals, plus case study analysis of key M&As.

Published By Datamonitor
17 Dec 2009 $11400
Buy
Report
Report

Pharmaceutical Company Outlook to 2014

Assess the outlook for the PharmaVitae universe of leading Rx pharma companies to 2014, in terms of both sales and operating performance. Analyze the industry by peer set, balance of launches / expiries, and therapeutic and molecule type focus.

Published By Datamonitor
23 Dec 2009 $7600
Buy
Report
Report

Pharmaceutical Key Trends 2010 - The patent cliff dominates but growth opportunities remain

An overview of key trends shaping the pharmaceutical industry today, as well as drivers and resistors that are set to play a central role in the future as companies look to increase sales and boost profitability.

Published By Datamonitor
17 Mar 2010 $11400
Buy
Report
Report

Pharmaceutical Licensing Overview - Risk-aversion breeds creativity as externalization intensifies

A comprehensive overview of licensing deals and strategies employed by the top 10 pharma companies during 2008-09, with intertwined case study analysis and an assessment of evolving trends observed in the global pharmaceutical licensing landscape.

Published By Datamonitor
24 Mar 2010 $15200
Buy
Report
Report

Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity

This report analyzes three emerging markets, Brazil, Russia and India as targets for HIV drug manufacturers. It discusses the commercial and regulatory environment, guidelines, domestic and multinational competition as well as market entry strategies.

Published By Datamonitor
25 May 2010 $3800
Buy
Report
Report

Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape

Overview of the Australian pharmaceutical market including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis and pharmaceutical company infrastructure analysis.

Published By Datamonitor
29 Jul 2010 $7600
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

No help is available.